RxDoctor Payments Data

Altory Miranda, MD

General Practice · Moseley, VANPI 1871891507

Payments from drug & device makers

$296in general payments, 2019–2025

Across 3 payments — averaging $98.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$143
  • Otsuka America Pharmaceutical, Inc.$77
  • Johnson & Johnson$75

What the payments were for

  • Food & beverage$296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$296 in reported general payments places this provider in the 50th percentile of 2,591 general practice providers in Virginia.

See all general practice providers in Virginia

Medicare billing

Part B allowed, 2024
$508,617
Medicare patients
518
Services billed
4,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,102$334,483
Avonex Pen (4 Pack)Interferon Beta-1a12$102,337
EntrestoSacubitril/Valsartan212$76,275
IngrezzaValbenazine Tosylate18$71,254
XareltoRivaroxaban188$64,478
TrulicityDulaglutide118$62,455
JardianceEmpagliflozin174$61,021
BiktarvyBictegrav/Emtricit/Tenofov Ala13$54,025
RexultiBrexpiprazole51$49,538
OzempicSemaglutide42$45,346
DovatoDolutegravir Sodium/Lamivudine25$36,674
TivicayDolutegravir Sodium33$29,707
JanuviaSitagliptin Phosphate91$26,066
MyrbetriqMirabegron77$24,137
Atorvastatin Calcium1,460$23,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$143$71,25418 claims
Johnson & JohnsonXarelto$75$64,478188 claims
Otsuka America Pharmaceutical, Inc.Rexulti$77$49,53851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,591 general practice providers in Virginia.

Other general practice in Moseley

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →